Stock analysts at Royal Bank Of Canada started coverage on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a report released on Thursday. The brokerage set an “outperform” rating on the biotechnology company’s stock.

ANAB has been the topic of a number of other research reports. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price target on shares of AnaptysBio in a research note on Tuesday. Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research note on Wednesday. Credit Suisse Group lifted their target price on AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Finally, Robert W. Baird initiated coverage on AnaptysBio in a research note on Monday, July 10th. They set an “outperform” rating and a $36.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $36.33.

Shares of AnaptysBio (ANAB) traded down 3.93% on Thursday, hitting $31.31. 397,565 shares of the stock traded hands. The company’s 50 day moving average is $32.24 and its 200 day moving average is $25.84. The stock’s market cap is $636.91 million. AnaptysBio has a one year low of $15.17 and a one year high of $33.58.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $3.45 million. On average, equities analysts forecast that AnaptysBio will post ($1.96) EPS for the current year.

WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/anaptysbio-inc-anab-now-covered-by-analysts-at-royal-bank-of-canada.html.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 491,294 shares of AnaptysBio stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $21.12, for a total transaction of $10,376,129.28. Following the transaction, the insider now owns 2,952,527 shares of the company’s stock, valued at approximately $62,357,370.24. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,133,940 shares of company stock worth $24,223,316.

Several hedge funds and other institutional investors have recently made changes to their positions in ANAB. Frazier Management LLC bought a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $102,354,000. Perceptive Advisors LLC bought a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $24,474,000. Marshall Wace North America L.P. bought a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $6,924,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of AnaptysBio in the 1st quarter valued at approximately $6,924,000. Finally, Artal Group S.A. grew its stake in shares of AnaptysBio by 459.4% in the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after buying an additional 205,310 shares in the last quarter. 71.35% of the stock is owned by institutional investors and hedge funds.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.